Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rodenhuis

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Cancer Research|October 15, 1988
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lungS Rodenhuis, R J Slebos, A J Boot, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|April 29, 1998
A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspirationM S de Lange, B Top, C Lambrechts, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'S Rodenhuis, A H Scaf, N H Mulder, et al.
British Journal of Cancer|May 1, 1996
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patientsE van der Wall, E J Rutgers, M J Holtkamp, et al.
Cancer Research|September 24, 1999
A search for new metabolites of N,N',N''-triethylenethiophosphoramideM J van Maanen, I M Tijhof, J M Damen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancerE van der Wall, D J Richel, Y H Kusumanto, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 1, 1990
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasmaJ H Beijnen, B R Smith, W J Keijer, et al.
Anti-Cancer Drugs|April 9, 1999
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic studyR van Gijn, W W ten Bokkel Huinink, S Rodenhuis, et al.
British Journal of Cancer|May 1, 1992
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspectsL T Vlasveld, E M Rankin, A Hekman, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2009
Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancerM E Straver, E J Th Rutgers, N S Russell, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Cancer Research|October 15, 1988
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lungS Rodenhuis, R J Slebos, A J Boot, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|April 29, 1998
A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspirationM S de Lange, B Top, C Lambrechts, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'S Rodenhuis, A H Scaf, N H Mulder, et al.
British Journal of Cancer|May 1, 1996
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patientsE van der Wall, E J Rutgers, M J Holtkamp, et al.
Cancer Research|September 24, 1999
A search for new metabolites of N,N',N''-triethylenethiophosphoramideM J van Maanen, I M Tijhof, J M Damen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1993
Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancerE van der Wall, D J Richel, Y H Kusumanto, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 1, 1990
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasmaJ H Beijnen, B R Smith, W J Keijer, et al.
Anti-Cancer Drugs|April 9, 1999
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic studyR van Gijn, W W ten Bokkel Huinink, S Rodenhuis, et al.
British Journal of Cancer|May 1, 1992
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspectsL T Vlasveld, E M Rankin, A Hekman, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2009
Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancerM E Straver, E J Th Rutgers, N S Russell, et al.
Pageof 15